Stock Track | HENLIUS Soars 6.36% in Morning Session on Clinical Trial Milestone, Canadian Approvals, and Strong Financials

Stock Track03-27

HENLIUS's stock price soared 6.36% during the morning trading session on Friday.

The surge follows significant positive developments for the company. HENLIUS announced that the first patient in China has been dosed in a Phase 1b/2 clinical study for HLX701, a potential treatment for advanced colorectal cancer. Additionally, the company recently received marketing approval from Health Canada for its denosumab biosimilar, BILDYOS, and for TUZEMTY, expanding its international market presence.

Investor sentiment was also bolstered by the company's strong financial performance. HENLIUS reported a 16.5% year-over-year increase in full-year 2025 revenue to RMB 6.67 billion, with a net profit attributable to shareholders of RMB 827 million. Analysis points to increased sales of core products like Han Qu You and Han Si Zhuang, coupled with overseas revenue that more than doubled compared to the previous year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156815607?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156815607","market":"nz","top_or_hot":-1,"title":"Stock Track | HENLIUS Soars 6.36% in Morning Session on Clinical Trial Milestone, Canadian Approvals, and Strong Financials","media":"Stock Track","content":"<p>HENLIUS's stock price soared 6.36% during the morning trading session on Friday.</p><p>The surge follows significant positive developments for the company. HENLIUS announced that the first patient in China has been dosed in a Phase 1b/2 clinical study for HLX701, a potential treatment for advanced colorectal cancer. Additionally, the company recently received marketing approval from Health Canada for its denosumab biosimilar, BILDYOS, and for TUZEMTY, expanding its international market presence.</p><p>Investor sentiment was also bolstered by the company's strong financial performance. HENLIUS reported a 16.5% year-over-year increase in full-year 2025 revenue to RMB 6.67 billion, with a net profit attributable to shareholders of RMB 827 million. Analysis points to increased sales of core products like Han Qu You and Han Si Zhuang, coupled with overseas revenue that more than doubled compared to the previous year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HENLIUS Soars 6.36% in Morning Session on Clinical Trial Milestone, Canadian Approvals, and Strong Financials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HENLIUS Soars 6.36% in Morning Session on Clinical Trial Milestone, Canadian Approvals, and Strong Financials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS's stock price soared 6.36% during the morning trading session on Friday.</p><p>The surge follows significant positive developments for the company. HENLIUS announced that the first patient in China has been dosed in a Phase 1b/2 clinical study for HLX701, a potential treatment for advanced colorectal cancer. Additionally, the company recently received marketing approval from Health Canada for its denosumab biosimilar, BILDYOS, and for TUZEMTY, expanding its international market presence.</p><p>Investor sentiment was also bolstered by the company's strong financial performance. HENLIUS reported a 16.5% year-over-year increase in full-year 2025 revenue to RMB 6.67 billion, with a net profit attributable to shareholders of RMB 827 million. Analysis points to increased sales of core products like Han Qu You and Han Si Zhuang, coupled with overseas revenue that more than doubled compared to the previous year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1156815607","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156815607","pubTimestamp":1774578524,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HENLIUS's stock price soared 6.36% during the morning trading session on Friday.The surge follows significant positive developments for the company. HENLIUS announced that the first patient in China...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"个股追踪|复宏汉霖早盘大涨6.36%，因临床试验里程碑、加拿大获批、财务状况强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"HENLIUS's stock price soared 6.36% during the morning trading session on Friday.The surge follows significant positive developments for the company. HENLIUS announced that the first patient in China has been dosed in a Phase 1b/2 clinical study for HLX701, a potential treatment for advanced colorectal cancer. Additionally, the company recently received marketing approval from Health Canada for its denosumab biosimilar, BILDYOS, and for TUZEMTY, expanding its international market presence.Investor sentiment was also bolstered by the company's strong financial performance. HENLIUS reported a 16.5% year-over-year increase in full-year 2025 revenue to RMB 6.67 billion, with a net profit attributable to shareholders of RMB 827 million. Analysis points to increased sales of core products like Han Qu You and Han Si Zhuang, coupled with overseas revenue that more than doubled compared to the previous year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156815607","isCrawlerRequest":true}